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Abstract: Mutations in two major genes, BRCA1 and BRCA2, account for up to 30% of families with hereditary breast 
cancer. Unfortunately, in most families there is little to indicate which gene should be targeted ﬁ  rst for mutation screening, 
which is labor intensive, time consuming and often prohibitively expensive. As BRCA1 is a tumor suppressor gene involved 
in various cellular processes, heterozygous mutations could deregulate dependent pathways, such as DNA damage response, 
and disturb transcriptional activity of genes involved in the downstream signaling cascade. We investigated gene expression 
proﬁ  ling in peripheral blood lymphocytes to evaluate this strategy for distinguishing BRCA1 mutation carriers from non-carriers. 
RNA from whole blood samples of 15 BRCA1 mutation carriers and 15 non-carriers from BRCA1 or BRCA2 families were 
hybridized to Agilent Technologies Whole Human Genome OligoMicroarrays (4 × 44 K multiplex format) containing 41,000 
unique human genes and transcripts. Gene expression data were analyzed with Welch’s t-tests and submitted to hierarchical 
clustering (GeneSpring GX software, Agilent Technologies). Statistical analysis revealed a slight tendency for 133 genes 
to be differentially expressed between BRCA1 mutation carriers and non-carriers. However, hierarchical clustering of these 
genes did not accurately discriminate BRCA1 mutation carriers from non-carriers. Expression variation for these genes 
according to BRCA1 mutation status was weak. In summary, microarray proﬁ  ling of untreated whole blood does not appear 
to be informative in identifying breast cancer risk due to BRCA1 mutation.
Keywords: microarray, gene expression proﬁ  le, peripheral blood mononuclear cells, hereditary breast cancer, BRCA1, 
molecular genetic diagnostics
Introduction
Breast cancer is the most common cancer in women in the western world, of which approximately ﬁ  ve 
to ten percent of cases are of hereditary origin. Two major susceptibility genes, BRCA1 and BRCA2, 
were identiﬁ  ed through positional cloning in 1994
1 and 1996
2 respectively. Mutations in these genes 
account for up to 30% of families with hereditary breast cancer. These genes are risk factors with by 
far the highest predictive value, and they may be targeted for analysis according to the familial pheno-
type. BRCA1 mutations are associated with female breast and ovarian cancer, while BRCA2 mutations 
are rather associated with female and male breast cancer and to a lesser extent with ovarian cancer. 
Despite these differences in familial phenotype, the majority of families present only early onset breast 
cancer and there is little to indicate which gene should be targeted ﬁ  rst for more efﬁ  cient mutation 
screening or if in fact one of the BRCA1 or BRCA2 gene is at cause.
BRCA1 is a tumor suppressor gene involved in various cellular processes, notably DNA damage 
response, cell cycle control, chromatin remodeling, ubiquitination and transcriptional regulation.
3,4 The 
involvement of BRCA1 in these processes is highlighted by its interaction with a variety of proteins, 
including DNA damage repair proteins (RAD50, RAD51, BRCA2, MLH1, FANCA), transcriptional 
activators and repressors (RNA polymerase II, RNA helicase A, histone deacetylase 1, CtBP1, ERalpha, 
AR, STAT1) and cell cycle checkpoint proteins (p53, cyclins and cyclin dependent kinases).
5 Microarray 
studies have shown that BRCA1 transcriptionally regulates genes involved in breast tumorigenesis, most 
notably those coding for p21
WAF1/CIP1, GADD45, 14-3-3σ, c-Myc and cyclin D1.
6 Hemizygosity for 
BRCA1 could thus have an effect on expression levels of these genes.42
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Microarray studies have also shown that 
constitutional mutations in BRCA1 and BRCA2 
inﬂ  uence the gene expression proﬁ  le of malignant 
tissues.
7–13 In primary tumors from breast epithelium, 
Hedenfalk et al. showed that there are different gene 
expression proﬁ  les in BRCA1 positive tumors, BRCA2 
positive tumors and sporadic tumors.
8 Comparison 
of gene expression patterns in ovarian cancers showed 
that BRCA1 and BRCA2 associated tumors differ 
signiﬁ  cantly in their gene expression proﬁ  les.
12
With regard to healthy tissues, studies of ﬁ  broblasts 
cultured from breast
14 and skin biopsies
15 showed that 
irradiated cells from heterozygous BRCA1 mutation 
carriers display gene expression proﬁ  les different 
from those of non-carriers
14 and those of BRCA2 
mutation carriers.
15 These results demonstrate the 
involvement of  BRCA1 and BRCA2 in DNA damage 
response and the potential existence of a distinct 
functional heterozygous phenotype for BRCA1 
carriers. This hypothesis was assessed through studies 
of irradiated human lymphocytes from heterozygous 
BRCA1 and BRCA2 mutation carriers.
16–18 These 
studies analyzed the cellular phenotype of irradiated 
lymphocytes and showed a deﬁ  cit in DNA damage 
response resulting in micronuclei formation in irradi-
ated G0 cells
17,18 and in an increased level of chro-
mosomal aberrations after irradiation.
16
These different studies show that gene expression 
proﬁ  les associated with BRCA1 or BRCA2 mutation 
status can be found in malignant tissues and in 
irradiated healthy tissue. However, these two 
approaches cannot be easily applied to diagnostic 
screening: the ﬁ  rst case requires a tumor sample 
and the second case requires irradiation (or treat-
ment with other DNA damaging agents) of fresh 
lymphocytes or cell lines. We therefore proposed 
to examine gene expression proﬁ  les of BRCA1 
mutation carriers and BRCA1 or BRCA2 non-carriers 
in an accessible tissue such as peripheral blood 
mononuclear cells (PBMCs). Our aim was to assess 
if a BRCA1-carrier proﬁ  le could be identiﬁ  ed in 
untreated samples. If so, this proﬁ  le could allow 
the development of a test for ﬂ  agging likely BRCA1 
mutation carriers. The interest of working with 
untreated samples is the broader range of samples 
accessible for testing, notably those drawn at distant 
locations and sent to the laboratory by mail. The 
routine treatment of such samples with DNA dam-
aging agents in a timely and homogeneous manner 
would not be practical.
The use of untreated PBMCs is relevant in light of 
the established links between DNA damage response, 
immunity and cancer.
19 Other studies have successfully 
used PBMCs to demonstrate that breast cancer affects 
gene expression patterns in peripheral blood cells 
during early stages of disease development.
20 Inter-
individual variation observed in peripheral blood
21–23 
was shown to be minimal in comparison to that 
observed associated with various diseases and 
disorders
21,23 such as cancer or infectious disease.
In the present study, we compared gene 
expression proﬁ  les in peripheral blood cells of 
BRCA1 mutation carriers who belong to high-risk 
breast cancer families with gene expression proﬁ  les 
of BRCA1 or BRCA2 mutation non-carriers in 
order to evaluate the possibility of setting up 
a microarray-based preliminary screening tool.
Materials and Methods
Case selection criteria
All samples were taken from members of high-risk 
breast cancer families ascertained through the 
Oncogenetic consultation at the Centre Jean Perrin. 
Individuals were asked to provide a blood sample 
and to sign an informed consent form approved by 
the CCPPRB regional ethics committee (Auvergne). 
Fifteen samples from patients with germline 
mutations of BRCA1 and ﬁ  fteen samples from 
family members without the familial mutation were 
selected for analysis. Mutation screening was 
performed by direct sequencing.
RNA isolation
Peripheral Blood Mononuclear Cells (PBMCs) were 
isolated on a density gradient. Brieﬂ  y, 3 ml of Pancoll 
(PAN Biotech GmbH, Aidenbach, Germany) was 
added to a LeucoSep tube (Dutscher, Brumath, 
France) and centrifuged to position the porous 
LeucoSep membrane on the Pancoll surface. 
Approximately 6 ml of heparinized blood was 
poured onto the membrane, and the tubes were 
centrifuged at 1000 g for 10 min at room temperature. 
After centrifugation, the interface containing 
PBMCs was collected and washed twice with PBS 
(Invitrogen, Carlsbad, CA). Total RNA was extracted 
with TRIzol reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. RNA 
quantity and quality were determined using the 
RNA 6000 Nano Assay kit on an Agilent 2100 
BioAnalyzer (Agilent Technologies, Palo Alto, CA), 
as recommended. A commercial pool of total RNA 43
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(ref. 636580 BD Biosciences Clontech, Heidelberg, 
Germany) extracted from normal human peripheral 
leukocytes of 13 healthy male/female Caucasians was 
used as a reference RNA cohybridized with the test 
sample (carriers or controls) in each microarray.
cRNA ampliﬁ  cation and labeling
Total RNA was ampliﬁ  ed and labeled with Cyanine 
5 for test samples (carriers and controls) and with 
Cyanine 3 for the reference using Agilent’s Low RNA 
Input Linear Ampliﬁ  cation Kit (Agilent Technolo-
gies, Palo Alto, CA) following the detailed protocol 
described in the kit manual (Manual Part Number 
G4140-90050 version 5.0.01). Brieﬂ  y, 1 μg of total 
RNA was reversed transcribed to double-strand 
cDNA using a poly dT-T7 promoter primer. Primer, 
template RNA and quality-control transcripts of 
known concentration and quality were ﬁ  rst denatured 
at 65 °C for 10 min and incubated for 2 hours at 40 °C 
with 5X ﬁ  rst strand Buffer, 0.1 M DTT, 10 mM 
dNTP, MMLV RT, and RNase-out. The MMLV RT 
enzyme was inactivated at 65 °C for 15 min. cDNA 
products were then used as templates for in vitro 
transcription to generate ﬂ  uorescent cRNA. cDNA 
products were mixed with a transcription master mix 
in the presence of T7 RNA polymerase and CY5 
labeled or CY3 labeled-CTP and incubated at 40 °C 
for 2 hours. Labeled cRNAs were puriﬁ  ed using 
QIAGEN’s RNeasy mini spin columns and eluted in 
30 μl of nuclease-free water. After ampliﬁ  cation and 
labeling, cRNA quantity and cyanine incorporation 
were determined using a nanodrop ND.1000 
UV-VIS-Spectrophotometer version 3.2.1(Agilent 
Technologies, Palo Alto, CA).
Sample hybridization
For each hybridization, 825 ng of Cyanine 3 labeled 
cRNA (reference) and 825 ng of Cyanine 5 labeled 
cRNA (carriers or controls) were mixed, fragmented, 
and hybridized at 65 °C for 17 hours to an Agilent 
44 K Whole Human genome Oligo Microarray 
containing 45,015 features representing 41,000 
unique probes. After washing, microarrays were 
scanned using an Agilent DNA microarray scanner. 
Feature extraction software (Agilent Technologies, 
Palo Alto, CA) was used to assess fluorescent 
hybridization signals and to normalize signals using 
linear regression and a Lowess curve-ﬁ  t technique. 
Reproducibility and reliability of each single 
microarray was assessed using Quality Control 
report data (Feature extraction, Agilent Technologies). 
Self-self and dye swap hybridizations were performed 
to check data quality and evaluate the importance of 
dye bias. For self-self hybridizations, aliquots of the 
same RNA sample were separately labeled with CY3 
and CY5 ﬂ  uorescent dyes and cohybridized to the 
same microarray.
Data analysis
Gene expression analysis was carried out using 
GeneSpring GX software (Agilent Technologies, 
Palo Alto, CA). Expression ratios were calculated 
(CY5 processed signal was divided by CY3 pro-
cessed signal), and normalized per chip to the 50th 
percentile and finally normalized per gene to 
medians. We worked on a pre-screened list of 
16,997 genes obtained after ﬁ  ltering the data for 
outliers, negative and positive controls, and on the 
quality ﬂ  ag CY5 and CY3 signals being “well above 
background”. To pass this last ﬂ  ag, CY5 and CY3 
net signals needed to be positive and signiﬁ  cant, with 
g(r)BGSubSignal greater than 2.6 g(r) BG_SD.
To determine if there were genes differentially 
expressed between mutation carriers and controls, we 
performed two Welch’s t-tests (P  0.01) on this pre-
screened list of genes: one without correction and one 
with Benjamini and Hochberg’s correction. Average 
linkage hierarchical clustering analysis was applied 
using Euclidean distance, and differentially expressed 
genes were annotated using the information from the 
Gene Ontology Consortium. Panther, Ingenuity Path-
ways Analysis (Ingenuity Systems®, www.ingenuity.
com) and FatiGO software were used to assess 
whether speciﬁ  c biological processes or molecular 
functions were differentially expressed, through the 
over-representation of groups of genes with functional 
links, rather than individual genes. Global molecular 
networks and comparison of canonical pathways were 
generated using Ingenuity Pathways Analysis.
Allele-speciﬁ  c transcript expression
Single-nucleotide primer extension was performed 
as described in the Supplementary Methods with 
the ABI Prism SnaPshot multiplex Kit (Applied 
Biosystems, Evry, France).
Results
Sample characteristics
Sample characteristics are listed in Table 1. We 
selected a group of ﬁ  fteen BRCA1 mutation carriers 44
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Table 1. Sample characteristics for BRCA1 mutation carriers and non-carriers.
Sample Family number Sex Age Diagnosis 
(Age)
Familial BRCA1 
mutation
Carrier 
Yes/No
Mutation 
type
Exon
R282 0017–01 F 74 Breast 
cancer (54)
c. 3841_3843delCA Yes Frameshift 11
R370 0278–30 F 48 No cancer C.3607CT Yes Stop 11
R694 0401–36 F 26 No cancer c. 68_69delAG Yes Frameshift 2
R632 0815–14 M 76 No cancer c. 4810CT Yes Stop 16
R286 0922–01 F 59 Breast 
cancer (51)
C.178CT Yes Stop 5
R333 0929–09 M 56 No cancer c. 4248_4249 del TG Yes Frameshift 13
R316 1197–08 M 44 No cancer c. 3839_3843delins4 Yes Frameshift 11
R365 1447–01 F 73 Breast 
cancer (70)
c. 4282ins41 Yes Frameshift 13
R366 1447–06 F 51 Breast 
cancer (37)
c. 4282ins41 Yes Frameshift 13
R443 1541–01 F 59 Breast 
cancer (50)
c. 4163dupA Yes Frameshift 12
R615 1971–03 F 76 No cancer c.4065_4068delTCAA Yes Frameshift 11
R642 2001–01 F 67 No cancer c. 3839_3843delins4 Yes Frameshift 119
R611 2001–08 F 68 Breast 
cancer (59)
c. 3839_3843delins4 Yes Frameshift 119
R673 2001–35 F 44 No cancer c. 3839_3843delins4 Yes Frameshift 119
R654 2001–59 F 33 No cancer c. 3839_3843delins4 Yes Frameshift 119
R080 0080–38 F 40 No cancer None* No
R360 0271–52 M 67 No cancer None* No
R608 0554–46 F 45 No cancer None* No
R606 0719–20 F 41 No cancer None* No
R698 0822–19 F 58 No cancer c. 4810CT No
R618 0998–38 F 32 No cancer c. 3839_3843delins4 No
R283 1119–01 F 38 No cancer None* No
R332 1212–43 F 36 No cancer c. 178CT No
R659 1317–08 F 22 No cancer None* No
R628 1393–08 F 38 No cancer c. 1504_1508del5 No
R609 1541–10 M 60 No cancer c. 4163dupA No
R617 1971–01 F 45 No cancer c. 4065_4068delTCAA No
R616 1971–16 F 37 No cancer c. 4065_4068delTCAA No
R674 2001–36 M 36 No cancer c. 3839_3843delins4 No
R683 2001–80 M 34 No cancer c. 3839_3843delins4 No
Non-carriers are healthy relatives tested negative by direct sequencing for a known BRCA1 or BRCA2 mutation present in their family. Only 
familial BRCA1 mutations are described in this table.
None: *When non-carriers belong to a BRCA2 family, the BRCA2 familial mutation is not described.
belonging to 11 distinct high-risk breast and ovarian 
cancer families and for whom 10 different BRCA1 
mutations were identiﬁ  ed by direct sequencing. 
At the time of blood sample collection, all mutation 
carriers were healthy and not undergoing treatment, 
although some of them had had breast or ovarian 
cancer 3 to 20 years previously. All mutations were 
deleterious nonsense codons or frameshifts, and were 45
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scattered throughout the gene. A comparison group 
of ﬁ  fteen healthy relatives without familial BRCA1 
or BRCA2 mutation was collected. The absence of 
mutation was veriﬁ  ed by direct sequencing for the 
mutation known to concern each family. Gender 
distribution was similar between carriers and controls 
(3 male and 12 female carriers; 4 male and 11 female 
controls). Age distribution was slightly lower among 
controls: 57 years for mutation carriers (range 26–76), 
versus 42 years for controls (range 22–67).
Distribution of signal intensity 
and abundance of transcripts
Signal intensity in lymphocytes was low. Although 
the dynamic range for the red and green channels 
was wide (from 30 to 60,000 for net signals), 
the median intensities were around 80 for both 
channels. As presented in Figure 1, the average 
BRCA1 signal, and therefore expression, was very 
low. The second major susceptibility gene involved 
in breast cancer risk, BRCA2, was not signiﬁ  cantly 
expressed in PBMCs. Among transcripts coding for 
BRCA1-interacting proteins, transcriptional regula-
tion proteins were more highly represented than 
those involved in DNA damage repair or cell cycle 
checkpoints. Proteins related to estrogen signaling 
(androgen and estrogen receptors) were not sig-
niﬁ  cantly expressed. Most of the known transcrip-
tional targets of BRCA1 were well represented.
Unsupervised analysis
The mutation carrier and non-carrier samples were 
cohybridized with an internal reference to Agilent 
44 K Whole Human genome Oligo Microarrays. 
Data were normalized using Feature Extraction 
software (Agilent Technologies, Palo Alto, CA) and 
analyzed with Genespring GX software (Agilent 
Technologies, Palo Alto, CA), resulting in a pre-
screened set of 16,997 genes. An unsupervised 
method was used to reveal distinct clusters accord-
ing to different parameters, such as BRCA1 muta-
tion status, gender, age or diagnosis. Average 
linkage clustering analysis using Euclidean dis-
tance was performed in both gene and experiment 
dimensions. This analysis did not show any clear 
subgroup of samples with similar expression pat-
terns that associated with BRCA1 mutation status 
(Fig. 2). The two main clusters observed in this 
dendogram were not associated with any of the 
parameters described above (family number, 
gender, age, diagnosis, BRCA1 mutation status). 
Some samples from the same family grouped 
together (three samples from family 2001: 
R673-R674-R683 and two samples from family 
1541: R443-R609) regardless of gender or BRCA1 
mutation status, although other samples from the 
same family were distant in the clustering.
Supervised analysis
Supervised analysis was performed to identify 
genes differentially expressed between BRCA1 
mutation carriers and controls, using a t-test based 
on the BRCA1 mutation status of each sample on 
the previous set of 16,997 genes, with a p-value 
ﬁ  xed at 0.01. This analysis revealed 133 genes 
differentially expressed between BRCA1 mutation 
carriers and controls.
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Figure 2. Hierarchical clustering performed on all samples «15 BRCA1 mutation carriers versus 15 non-carriers» in both the experiment and the 
gene dimensions using a pre-screened list of 16,997 genes. Branches are color coded according to the family number of each sample.
Hierarchical clustering
Hierarchical clustering in both gene and experiment 
dimensions using these 133 genes (Fig. 3) showed 
two main clusters with a positive predictive value 
of 100% and a negative predictive value of 80%. 
The dendogram branches show eleven of the 
15 BRCA1 mutation carriers grouped together in a 
ﬁ  rst cluster, while the second cluster contains three 
subgroups in which four BRCA1 mutation carriers 
are misclassified with non-carriers. These four 
samples were not distinguishable from other BRCA1 
mutation carriers by their gender, age, diagnosis, 
BRCA1 mutation type or by the functional domain 
affected by the mutation. None of their characteristics 
allowed us to exclude them from further analysis.
Gene list annotation
Among the 133 differentially expressed genes, 
105 corresponded to known genes with a unique 
identiﬁ  er, and 81 could be classiﬁ  ed in a Panther 
database (listed by function in Table 2). Transcrip-
tion and translation functions were fairly well 
represented, with a subunit of RNA polymerase 
I (POLR1D), a putative RNA helicase (DDX55), 
and zinc finger transcription factors (ZZEF1, 
ZFYVE28, PRDM1) tending to be over-expressed 
in the BRCA1 mutation carrier group. Immune-
response genes were also well represented, with 
nine genes, including an antigen of the major 
histocompatibility complex (HLA-E), an antibacte-
rial response protein (C1QBP), and a tumor sup-
pressor gene involved in B-cell differentiation 
(KLF6) differentially expressed. Biological 
processes linked to other BRCA1 functions such 
as cell cycle control and DNA repair were less 
represented. Three genes involved in oncogenesis, 
including the oncogenes VAV3 and YES1, tended 
to be up-regulated in the BRCA1 mutation carriers 
group. 
Using Ingenuity Pathways Analysis software, 
67 genes could be used to generate global molec-
ular networks, which identiﬁ  ed 13 independent 
networks mainly involving genes linked to cancer 
disease. No overlap was observed between these 
13 networks with the BRCA1 global molecular 
network, since no genes were common to our set 
of 133 genes and the global molecular network of 
35 genes connected to BRCA1 and selected from 
the Ingenuity’s Knowledge database. A search of 
all molecules upstream and downstream of 47
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BRCA1, for all types of relationships, yielded 314 
genes linked to BRCA1. Comparison of this list to 
the 133 differentially expressed genes identiﬁ  ed 
two in common (DDB2 and CCL5), both coding 
for proteins whose expression was previously 
shown to be induced by BRCA1.
24,25
The transcript DDB2 codes for Damaged DNA 
Binding Protein and was shown to be transcription-
ally up-regulated by wild type BRCA1 in a 
p53-dependent manner upon DNA damage.
25 In 
our dataset, it tended to be slightly over-expressed 
in BRCA1 mutation carriers, even though BRCA1 
should be less functional in this group. The other 
transcript, CCL5, codes for an interferon-inducible 
gene involved in apoptotic cell death, and has been 
found to be up-regulated by BRCA1 in breast 
cancer cell lines.
24 Like DDB2, this gene tended 
to be slightly overexpressed in BRCA1 mutation 
carriers in our dataset.
None of the other BRCA1-interacting proteins 
and transcriptional targets cited previously and 
presented in Figure 1 were present among the 
133 differentially expressed genes (Table 2). 
Fold-changes in gene expression for differentially 
expressed genes had little amplitude, and the 
standard deviation within the same group was 
large. As an example, in Figure 4A, although the 
VAV3 transcript tended to be slightly more repre-
sented in BRCA1 mutation carriers, the log ratio 
variation between the two groups was signiﬁ  cant 
but weak.
Supervised analysis with correction 
of false discovery rate
In order to limit the number of signiﬁ  cant genes 
due to random chance among the 16,997 tested 
genes, we performed a t-test with Benjamini and 
Hochberg multiple testing correction with a p-value 
less than 0.01. This analysis did not show any genes 
differentially expressed between BRCA1 mutation 
carriers and controls.
Supervised analysis of BRCA1-
interacting proteins and targets
Expression profiles of 52 BRCA1-interacting 
proteins and transcriptional targets were compared 
to mutation status. None of these genes appeared 
signiﬁ  cant in a t-test with a p-value less than 0.05. 
Two genes, STAT1 and TERT, had p-values less 
than 0.10. BRCA1 gene expression levels are 48
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levels of the mutant allele compared to the 
wild-type allele. This reduction of BRCA1 mutant 
transcript may limit any deleterious effects of 
mutant BRCA1 protein on its transcriptional 
targets or partners, resulting in a recessive effect 
at the cellular level. This elimination of the mutant 
transcript, however, did not result overall in detect-
ably lower levels of expression of BRCA1 itself; 
it seems that inter-individual variation was too 
great for direct detection of mutation carriers. This 
inter-individual variation could be due to con-
founding factors, such as time of blood sampling, 
menstrual cycle phase, stress, dietary patterns 
and/or intake of medications.
Another source of error to consider is 3’-end 
bias. Reverse-transcription using oligo-dT primers 
biases this study in favor of detecting the 3’end of 
transcripts in the hybridization step, and is not 
suitable for detecting variants alternatively spliced 
far upstream of the 3’end. To address this issue, 
other strategies could be employed, notably random 
priming of the RT-PCR reaction,
26 and the use of 
exon-speciﬁ  c arrays, in which probes designed to 
interrogate variant transcripts are included in the 
array.
Comparing our results with microarray data from 
other groups obtained after irradiation conﬁ  rms that 
BRCA1 is a response gene, and a stimulus such as 
DNA damage is necessary to reveal the phenotype. 
This haploinsufﬁ  ciency is not detectable in the 
absence of exceptional stress. Cancer risk associ-
ated with BRCA1 mutation can thus be explained 
by two models. First, random loss of the wild-type 
allele in sensitive tissues such as breast and ovary 
results in a small population of BRCA1-null cells, 
which are now highly susceptible to oncogenesis. 
This model is borne out by the observation that loss 
of the wild-type allele is indeed a very common and 
early step in breast oncogenesis in mutation carriers. 
A second, non-exclusive model proposes that a 
single allele of BRCA1 is sufﬁ  cient for normal 
cellular metabolism, but is insufﬁ  cient to adequately 
respond to genotoxic stress. Irradiation thus reveals 
a phenotype not otherwise detectable. The 
sub-normal response to DNA damage may result 
in the ﬁ  xation of mutations and the early steps of 
oncogenesis.
Previous studies demonstrate that gene expression 
proﬁ  les can be a powerful tool to predict BRCA1 
mutation status in malignant tissue or in irradiated 
healthy tissue.
8,10,12,14,15 However, the different 
studies rarely retain the same differentiating genes 
shown in Figure 4B; no signiﬁ  cant changes in gene 
expression were observed (p = 0.16).
Discussion
We compared gene expression proﬁ  les of untreated 
PBCMs from 15 BRCA1 mutation carriers and 
15 non-carriers. Of 16,997 genes tested, statistical 
analysis revealed 133 to be differentially expressed 
at p  0.01. This number was smaller than the 
approximately 170 genes expected by random 
chance. Hierarchical clustering performed on the 
133 differentially expressed genes revealed four 
BRCA1 mutation carrier samples misclassiﬁ  ed in the 
non-carrier group. Among this list of differentially 
expressed transcripts, 60% could be annotated through 
Panther and FatiGO databases: these were mainly 
involved in cellular metabolic processes and to a 
lesser extent in immune response and transcription. 
There was a weak variation in their log-ratio expres-
sion between BRCA1 mutation carriers and non-car-
riers. Although supervised analysis revealed a 
tendency for these genes to be differentially expressed 
in BRCA1 mutation carriers, these genes could not 
be used to deﬁ  ne a robust and reliable signature for 
BRCA1 heterozygosity in PBMCs. The variation in 
expression was too weak between carriers and 
controls, and they did not allow us to discriminate all 
BRCA1 mutation carrier samples from BRCA1 or 
BRCA2 non mutation carrier samples.
Considering the very large number of genes 
tested (nearly 17,000) and the small number of 
samples (30), it is likely that random chance will 
yield some genes which are not really signiﬁ  cant 
even though they appear to discriminate between 
the two populations. Using a more stringent test to 
control this false discovery rate, we did not ﬁ  nd 
any genes passing this statistical restriction ﬁ  lter. 
Moreover, BRCA1 itself had low signal intensity 
in PBMCs and, like its partners and transcriptional 
targets, did not show any signiﬁ  cant changes in 
gene expression correlated to its mutation status.
This lack of difference in gene expression pat-
terns between BRCA1 mutation carriers and con-
trols could be due in part to an mRNA surveillance 
pathway, Nonsense Mediated Decay (NMD), 
which eliminates mRNAs harboring truncating 
mutations, thus limiting the production of truncated 
proteins with downstream deleterious effects. 
The majority of the mutant BRCA1 transcripts 
were tested for NMD (Supplementary Fig. 1) in 
PBMCs and most showed signiﬁ  cantly reduced 53
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and a large number of false positives are to be 
expected due to the small population sizes.
27 By 
examining gene expression proﬁ  les of BRCA1 
mutation carriers and non-carriers in untreated 
PBMCs, it seems difﬁ  cult to accurately distinguish 
carriers from non-carriers. This lack of a sufﬁ  -
ciently robust BRCA1 mutation carrier signature 
in untreated samples unfortunately inhibits the 
development of a pre-screening tool based on 
samples that are drawn at some time and distance 
from the analyzing laboratory or which for other 
reasons cannot undergo treatment appropriate to 
reveal the heterozygous phenotype.
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Supplementary Data
Allele-speciﬁ  c transcript expression
Genomic DNA was extracted from peripheral blood using standard methods. Samples were genotyped 
for two common single nucleotide polymorphisms (SNPs): c.2612CT (SNP ID rs 799917, located in 
exon 11 of BRCA1) and c.4837AG (SNP ID rs 1799966, located in exon 16 of BRCA1). We selected 
samples that were heterozygous for one of these polymorphisms (ten out of ﬁ  fteen). Complementary 
cDNA was synthesized from 1–2.5 μg total RNA using RT2 PCR Array ﬁ  rst strand kit (SuperArray 
Bioscience Corporation, Frederick, MD). Before reverse transcription, a genomic DNA elimination 
step was performed according to the manufacturer’s instructions. Ampliﬁ  cation primers (shown in 
Supplementary Table 1) were designed using Primer Express software (Applied biosystems, Evry, 
France) so that they would surround these SNPs and were provided by MWG Biotech (Roissy, France). 
Ampliﬁ  cation was performed using reagents purchased from Applied Biosystems (Evry, France) in a 
Primus HT thermocycler (MWG Biotech, Roissy, France). PCRs were carried out in a ﬁ  nal volume 
of 10 μl containing 50 ng of gDNA or 75 ng of cDNA, 0.4 μM reverse and forward primers, 
(each deoxynucleotide triphosphate at 400 μM), 1.5 mM MgCl2 contained in 10X PCR Buffer, 0.6 U 
Use of Gene Expression Proﬁ  les of Peripheral Blood 
Lymphocytes to Distinguish BRCA1 Mutation Carriers
in High Risk Breast Cancer Families
Marie-Laure Vuillaume, Nancy Uhrhammer, Véronique Vidal, Valérie Sylvain Vidal, 
Valérie Chabaud, Beline Jesson, Fabrice Kwiatkowski and Yves-Jean Bignon
Supplementary Figure 1. Relative abundance of mutant “MU” versus wild type “WT” BRCA1 alleles expressed in peripheral blood lymphocytes. 
Quantitative analysis of allelic ratios in mRNA and genomic DNA (gDNA) was performed using the SnaPshot technique (Applied Biosystems, 
Foster City, CA). Alleles were discriminated with heterozygous single nucleotide polymorphisms present in the coding sequence of BRCA1. 
Normalization was performed by dividing the observed values by those obtained for the corresponding genomic DNA.
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6 AmpliTaq DNA polymerase (Applied biosystems, 
Evry, France). Thermocycling conditions were: 
94 °C for 5 min followed by 30 cycles of 94 °C for 
20 sec, 54 °C for 20 sec and 72 °C for 20 sec with 
a ﬁ  nal extension step of 72 °C for 7 min. PCR 
products were puriﬁ  ed in a one-step reaction by 
the addition of 1 μl of ExoSap reagent (Applied 
biosystems, Evry, France) to 5 μl of PCR products 
in a ﬁ  nal volume of 7 μl. The mixture was incu-
bated at 37 °C for 30 min, followed by enzyme 
deactivation at 80 °C for 30 min. Puriﬁ  ed PCR 
products were then analyzed using a primer exten-
sion method (SNaPshot). Extension primers 
(shown in Supplementary Table 1) were designed 
to anneal to the ampliﬁ  ed DNA template immedi-
ately adjacent to the heterozygous single nucleotide 
polymorphim site. Single nucleotide primer exten-
sion was performed in a ﬁ  nal volume of 9 μl with 
2 μl of puriﬁ  ed PCR products, 3 μl of SNaPshot 
reaction mix (Applied biosystems, Evry, France) 
and 0.17 μM of a speciﬁ  c primer related to the 
heterozygous SNP analyzed. After puriﬁ  cation 
through a sephadex column, the extended primers 
labelled with different ﬂ  uorescent dyes were run 
on an ABI 3100 capillary electrophoresis instru-
ment and analyzed with GeneMapper software 
(Applied biosystems, Evry, France). Peak area 
ratios were calculated to measure the relative 
amount of the two alleles for cDNA and genomic 
DNA. Normalization was performed by divid-
ing the peak area ratios obtained for cDNA by 
those obtained for the corresponding genomic 
DNA which was deﬁ  ned as 1. Three independent 
experiments (PCR and SNaPshot reactions) were 
performed for each sample.